Many cancers don’t need to be attacked right away. This piece explains when careful monitoring can be a smart, less harmful option and which cancers doctors often watch instead of treating immediately.
Doctors have started to accept that immediate treatment is not always the best move for every diagnosis. “The fact that so many cancers will never kill you is not a justification for not knowing, because there is still plenty of room for ‘watchful waiting,’ as well as interventions that may improve quality of life even if they don’t extend life,” Dr. Marc Siegel, Fox News senior medical analyst, told Fox News Digital. That idea sits at the center of a growing shift toward more tailored care and fewer one-size-fits-all surgeries and chemo regimens.
Screening and smarter therapies have changed the conversation about timing. “The fact that cancers are occurring earlier is a justification for heightened screenings, not the opposite,” Siegel added. “Information is power — what you do with that information is based on clinical judgment and the art of medicine.”
Prostate cancer is a clear example where less can sometimes be more. “With respect to prostate cancer, for most low-risk cancers (Gleason 6 or grade group 1), we recommend initial observation and surveillance rather than immediate treatment,” he told Fox News Digital. “For high-grade tumors like Gleason 8, 9 or 10, we believe they progress quickly, so we recommend treatment to prevent the risk of metastasis,” said Punnen, who is also vice chair of research and a professor with the Desai Sethi Urology Institute at UHealth. “For low-risk tumors, we think they pose little risk, so we recommend just observation.”
Even when doctors choose observation, monitoring is active and deliberate. “But in the end, we can’t be sure, so our approach to observation includes serial monitoring of cancer status with PSA, MRI and occasional biopsy to ensure the tumor isn’t progressing.” That steady check-in keeps options open while avoiding treatments that would cause immediate side effects for little or no survival gain.
Early-stage breast disease like DCIS is another condition where watchful waiting has traction. “These results suggest that in the short term, active monitoring is a reasonable approach to management of low-risk DCIS,” the lead researcher said in a press release. “If longer-term follow-up supports the safety of active management from a cancer outcome standpoint, this approach could be considered as an option for women with this condition.”
Researchers are also tuning into patients’ emotional experience under observation. “But it is also critical that we understand how women feel when they are living with this ‘watch and wait’ approach and how it impacts their overall quality of life.” That balance between physical risk and mental wellbeing factors heavily into shared treatment decisions.
Some lymphomas and leukemias grow very slowly and often don’t demand immediate therapy. “This approach may be started after the initial diagnosis or after relapse, depending on the situation,” the foundation states on its website. “Active treatment is started if the patient begins to develop lymphoma-related symptoms or if there are signs that the disease is progressing.”
Chronic lymphocytic leukemia is another slow-marching disease where patience can be a plan. “I believe it’s fair to conclude that ‘watch-and-wait’ should remain the standard of care in the era of targeted drugs,” said researcher Petra Langerbeins, M.D., when presenting the findings. For many patients, delaying systemic therapy until symptoms emerge preserves quality of life without sacrificing long-term control.
Surgery isn’t always the default for other tumors either, especially when the risks of an operation are high. “It’s usually also considered for cancer that is lower-grade, low-volume and slow-growing,” the above source stated. In elderly patients or those with serious health issues, doctors may choose hormones or close surveillance over immediate invasive steps.
Small kidney masses and tiny thyroid cancers often fall into the watchful-waiting category. “Shared decision-making about active surveillance should consider risks of intervention/competing mortality versus potential oncologic benefits of intervention,” the UAU states in its guidance. Long-term registries show cancer-specific survival is nearly identical for some patients who delay surgery, which helps explain why observation is a common option.
Not every diagnosis should be watched, and not every patient is a candidate for surveillance. Choices depend on tumor biology, overall health and personal priorities, so ongoing conversation with clinicians matters. Open dialogue and careful follow-up let patients avoid unnecessary harm while preserving the option to act if the disease changes.
